Vaccinex (VCNX) News Today $6.72 -0.18 (-2.61%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 7:28 PM | finance.yahoo.comVaccinex, Inc. (VCNX)July 20, 2024 | msn.comInvestors Await Key Earnings Reports as US Futures Tread Water in Friday's PremarketJuly 20, 2024 | msn.comInvestors Await Key Earnings Reports as US Futures Tread Water in Friday's PremarketJune 6, 2024 | globenewswire.comVaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's DiseaseMay 16, 2024 | finanznachrichten.deVaccinex, Inc.: Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | investorplace.comVCNX Stock Earnings: Vaccinex Reported Results for Q1 2024May 15, 2024 | globenewswire.comVaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 14, 2024 | investing.comVaccinex faces Nasdaq compliance challengeApril 2, 2024 | investorplace.comVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023April 2, 2024 | globenewswire.comVaccinex Reports 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 6, 2024 | investing.comVaccinex CFO Scott Royer to retire, Jill Sanchez steps inMarch 2, 2024 | morningstar.comVaccinex Inc VCNXFebruary 21, 2024 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus TechnologyFebruary 21, 2024 | markets.businessinsider.comVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery PlatformFebruary 21, 2024 | finance.yahoo.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 21, 2024 | globenewswire.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 19, 2024 | marketbeat.comTrading was temporarily halted for "VCNX" at 07:02 PM with a stated reason of "News pending."February 15, 2024 | markets.businessinsider.comVaccinex Announces 1-For-14 Reverse Stock SplitFebruary 15, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Trading LowerFebruary 15, 2024 | globenewswire.comVaccinex, Inc. Announces Reverse Stock SplitFebruary 12, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex IncFebruary 8, 2024 | msn.comVaccinex Inc Secures $3.7M in Private Placement DealFebruary 7, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Popping OffFebruary 7, 2024 | markets.businessinsider.comVaccinex Announces Pricing of $3.7 Million PIPE FinancingDecember 4, 2023 | finance.yahoo.comNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleNovember 13, 2023 | finance.yahoo.comVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 31, 2023 | finance.yahoo.comVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingOctober 26, 2023 | finance.yahoo.comVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesOctober 6, 2023 | markets.businessinsider.comWhy Is Vaccinex (VCNX) Stock Up 26% Today?September 29, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 29, 2023 | marketwatch.comVaccinex Shares Slide Premarket After Stock OfferingSeptember 29, 2023 | finance.yahoo.comVaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 28, 2023 | stockhouse.comVaccinex's Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationSeptember 28, 2023 | finance.yahoo.comVaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationSeptember 27, 2023 | finance.yahoo.comVaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® ApplicationSeptember 26, 2023 | benzinga.comVaccinex Recent Insider ActivitySeptember 22, 2023 | marketwatch.comVaccinex Board to Implement 1-for-15 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comVaccinex, Inc. Announces Reverse Stock SplitAugust 14, 2023 | finance.yahoo.comVaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJune 1, 2023 | finance.yahoo.comVaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ETMay 31, 2023 | benzinga.comVaccinex Stock (NASDAQ:VCNX), DividendsMay 17, 2023 | seekingalpha.comVaccinex GAAP EPS of -$0.10, revenue of $0.55MMay 16, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 25, 2023 | finance.yahoo.comVaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of PepinemabApril 12, 2023 | finance.yahoo.comVaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian CellsApril 3, 2023 | finance.yahoo.comVaccinex Announces Private Placement with Commitments of $5.0 MillionApril 3, 2023 | finance.yahoo.comVaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical ProgramsMarch 23, 2023 | finance.yahoo.comVaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity ConferenceMarch 21, 2023 | finance.yahoo.comVaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here VCNX Media Mentions By Week VCNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VCNX News Sentiment▼0.660.61▲Average Medical News Sentiment VCNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VCNX Articles This Week▼50▲VCNX Articles Average Week Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CPIX News Today LEXX News Today IMRX News Today LPCN News Today XLO News Today RVPH News Today VYNE News Today CLNN News Today EQ News Today ALZN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VCNX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.